Antisense Oligonucleotides Targeting Parasite Inositol

1,4,5-Trisphosphate Receptor Inhibits Mammalian Host Cell Invasion by Trypanosoma cruzi

Muneaki Hashimoto¹, Takeshi Nara¹, Hiroko Hirawake¹, Jorge Morales¹, Masahiro Enomoto², Katsuhiko Mikoshiba^{3,4}

¹Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan, ²Division of Signaling Biology, Ontario Cancer Institute, Toronto, ON, Canada M5G 1L7, ³Laboratory for Developmental Neurobiology, RIKEN Brain Science Institute, Saitama 351-0198, Japan, ⁴Calcium Oscillation Project, International Cooperative Research Project and Solution-Oriented Research for Science and Technology, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan

Correspondence and requests for materials should be addressed to T.N. (tnara@juntendo.ac.jp) or K.M. (mikoshiba@brain.riken.jp)

Supplementary information

Supplementary Figure Legends

Figure S1 | Life span of TcIP₃R protein in *Trypanosoma cruzi* epimastigotes.

Full-length image of western blots of epimastigotes probed with anti-TcIP₃R antibody (A) and with anti-tubulin antibody (B). *T. cruzi* epimastigotes were incubated in LIT medium supplemented with 200 µg/mL cycloheximide (CHX) for the indicated time, collected by centrifugation at 1,500 x g for 10 min at 4°C, and lysed by sonication in PBS supplemented with protease inhibitor cocktail (cOmplete Mini, Roche Diagnostics K.K., Tokyo, Japan). The cell extracts were separated by SDS-PAGE and transferred to a PVDF membrane (Immobilon[®]-P, EMD Millipore Corporation, Billerica, MA). Western blots were probed with anti-TcIP₃R antibody or with anti-tubulin antibody, reacted with AP-conjugated secondary antibody, and developed using Immobilon[®] Western AP substrate (Milipore). Imaging was processed using ChemiDocTM XRS+ system (Bio-Rad Laboratories, Inc., Tokyo, Japan). M; molecular weight marker. A dashed line indicates a cropping area in Figure 1A. High background signals in panel A are due to the enhanced exposure for detection of the native, full-length TcIP₃R and likely due to the cross-reaction of anti-TcIP₃R antibody with degraded TcIP₃R.

Figure S2 | Life span of EGFP-TcIP₃R and EGFP in the transgenic *T. cruzi* epimastigotes. Full-length image of western blots of epimastigotes overexpressing EGFP-TcIP₃R fusion protein (A and B) or EGFP (C and D). Epimastigotes overexpressing EGFP-TcIP₃R were incubated with 200 μ g/mL CHX for the indicated time, collected by centrifugation, and lysed by sonication. The cell extracts were separated by SDS-PAGE and transferred to a PVDF membrane. The resulting membrane was cut horizontally into 2 pieces; one with higher molecular weight was probed with anti-TcIP₃R antibody (A) and the other with low molecular weight was reacted with anti-tubulin antibody (B), followed by chemiluminescent detection using SuperSignal[®] West Dura Extended Duration Substrate (Thermo Fisher Scientific) and Immobilon[®] Western AP substrate (Milipore), respectively. Imaging was performed using LAS4000 (GE Healthcare Japan Corporation, Tokyo, Japan). Likewise, epimastigotes overexpressing EGFP were processed as above, and western blots were probed with anti-EGFP antibody (C) and anti-tubulin antibody (D) and developed colorimetrically. M; molecular weight marker. See also legends for Supplementary Figure S1.

Figure S3 | **Expression levels of TcIP₃R in** *T. cruzi* **trypomastigotes.** Full-length image of western blots of trypomastigotes probed with anti-TcIP₃R antibody (A) and with anti-tubulin antibody (B). Western blots were processed essentially as in Figure S1. Note that TcIP₃R was undetectable. High background signals in panel A are due to the enhanced exposure for detection of the native, full-length TcIP₃R and likely due to the cross-reaction of anti-TcIP₃R antibody with degraded TcIP₃R. M; molecular weight marker. See also legends for Supplementary Figure S1.

Figure S4 | Inhibition of EGFP-TcIP₃R expression in the transgenic *T. cruzi* **trypomastigotes by treatment with phosphorothioate antisense TcIP₃R oligonucleotide.** Trypomastigotes overexpressing EGFP-TcIP₃R were treated with either Antisense 5995 or the complementary Sense 5995S oligonucleotide for the indicated time. Western blots were processed essentially as in Figure S2 and probed with anti-EGFP antibody (A) or anti-tubulin antibody (B). The lysate of EGFP-TcIP₃R-expressing epimastigotes without treatment was loaded as expression control. M; molecular weight marker.

Figure S1



Figure S2



Figure S3



Figure S4

